SPY002 clinical trials
SPY002 is named as an intervention in 2 current clinical trials in our USA, Germany, Italy, Belgium, Poland, Austria, Czechia, Brazil, Mexico, South Korea, Taiwan, Australia, India, France, Spain, Switzerland, Turkey, Canada, Japan and Israel registers. 1 is recruiting patients now. All registered phases are Phase 2. The lead sponsor is Spyre Therapeutics, Inc. The most-studied condition is Ulcerative Colitis. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
Patient leaflets for SPY002
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of SPY002
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395 · Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis
|
Phase 2 | Recruiting | Spyre Therapeutics, Inc | USA, India, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
|
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294 · Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis
|
Phase 2 | By invitation | Spyre Therapeutics, Inc | USA, Germany, Italy, Belgium, Poland, Austria, Czechia, Brazil, Mexico, South Korea, Taiwan, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
SPY002 in the EU trials register (CTIS)
2 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing SPY002. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease
2025-524640-35-00 · Digestive System Diseases
|
Phase 2 | Ongoing | Spyre Therapeutics Inc | Croatia, Poland, Austria + 12 more |
|
Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis
2025-521242-26-00 · CTIS ↗ · Digestive System Diseases
|
Phase 2 | Ongoing | Spyre Therapeutics Inc | Belgium, Hungary, Lithuania + 13 more |
Conditions studied with SPY002
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Spyre Therapeutics, Inc | 2 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about SPY002 trials
How many clinical trials are testing SPY002?
2 current trials in our USA, Germany, Italy, Belgium, Poland, Austria, Czechia, Brazil, Mexico, South Korea, Taiwan, Australia, India, France, Spain, Switzerland, Turkey, Canada, Japan and Israel registers name SPY002 (also registered as SPY002-091) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are SPY002 trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in USA, 1 with sites in Germany, 1 with sites in Italy, 1 with sites in Belgium, 1 with sites in Poland, 1 with sites in Austria, 1 with sites in Czechia, 1 with sites in Brazil, 1 with sites in Mexico, 1 with sites in South Korea, 1 with sites in Taiwan, 1 with sites in Australia, 1 with sites in India, 1 with sites in France, 1 with sites in Spain, 1 with sites in Switzerland, 1 with sites in Turkey, 1 with sites in Canada, 1 with sites in Japan and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors SPY002 clinical trials?
The lead sponsor is Spyre Therapeutics, Inc. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how SPY002 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SPY002 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SPY002 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.